Neuroprotect Sp. z o.o.

Warsaw 15 trials 6 recruiting

15 Registered trials

6 Currently recruiting

Organisation

Neuroprotect Sp. z o.o.

Location

Warsaw, Poland

Identifier

ORG-100048046

Address

Ul. Klaudyny 16c, 01-684, Poland

Departments

-
#40602:Centrum Medyczne NeuroProtect
1
4107
Centrum Medyczne Neuroprotect
Centrum Medyczne NeuroProtect
Department of Clinical Research
N/A
NA
ND

Clinical trials at this site (15)

Search interface

SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures Pending

2025-520587-18-00 Focal Onset Seizures 4
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in… Pending

2025-525127-27-00 Generalized Myasthenia Gravis 9
A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS) Recruiting

2024-512536-29-00 Amyotrophic Lateral Sclerosis (ALS) 4 2025-02-28
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis Recruiting

2023-507539-40-00 Myasthenia Gravis 4 2024-07-19
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by … Recruiting

2024-516739-29-00 Relapsing-remitting multiple sclerosis 4 2019-01-23
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasti… Recruiting

2024-517745-14-00 Multiple Sclerosis Spasticity 4 2025-09-24
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S… Ended

2022-501622-37-00 Multiple Sclerosis 5 2024-01-16
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended

2023-505974-14-00 Multiple Sclerosis (MS) 5 2022-06-23
“A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended

2023-503289-22-00 Relapsing Multiple Sclerosis 4 2024-07-05
AMX0035 and Progressive Supranuclear Palsy Ended

2023-505893-14-00 Progressive Supranuclear Palsy 5 2024-06-04
A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended

2023-505396-71-00 Early Alzheimer’s Disease with Biomarkers of Inflammati 4 2024-03-01
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease Ended

2023-506872-29-00 Alzheimer's Disease 4 2023-04-13
A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended

2023-506170-12-00 Alzheimer’s Disease 4 2021-10-18